Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$13.29 +2.1%	$0.00	$11.06 ▼ $63.00	$254.54M	1.52	132,690 shs	81,448 shs
CLDX Celldex Therapeutics	$23.35 +0.6%	$21.18	$14.40 ▼ $47.00	$1.54B	1.13	1.00 million shs	969,956 shs
INVA Innoviva	$18.72 -1.1%	$19.99	$16.67 ▼ $22.00	$1.19B	0.37	903,609 shs	885,574 shs
NVAX Novavax	$7.47 -2.2%	$6.98	$5.01 ▼ $17.81	$1.24B	2.69	4.74 million shs	4.88 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	-1.21%	0.00%	-13.55%	-98.30%	-98.30%
CLDX Celldex Therapeutics	-2.72%	+1.09%	+7.25%	+18.65%	-40.93%
INVA Innoviva	-1.87%	-4.83%	-8.51%	+3.73%	+7.07%
NVAX Novavax	-2.55%	+9.14%	+17.72%	+14.54%	-50.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBIO Crescent Biopharma	3.2224 of 5 stars	3.8	0.0	3.7	2.8	1.7	0.6
CLDX Celldex Therapeutics	1.9753 of 5 stars	4.4	1.0	0.0	2.2	0.0	0.0
INVA Innoviva	3.9937 of 5 stars	3.5	0.0	4.2	1.6	1.7	1.9
NVAX Novavax	4.3735 of 5 stars	3.1	1.0	4.7	1.9	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Crescent Biopharma	3.50	Strong Buy	$25.67	93.13% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	114.61% Upside
INVA Innoviva	3.00	Buy	$40.33	115.46% Upside
NVAX Novavax	2.25	Hold	$15.86	112.28% Upside

Current Analyst Ratings Breakdown

Latest CBIO, INVA, NVAX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Crescent Biopharma	$10K	25,981.95	N/A	N/A	$8.24 per share	1.61
CLDX Celldex Therapeutics	$7.02M	220.79	N/A	N/A	$11.26 per share	2.07
INVA Innoviva	$358.71M	3.28	$3.39 per share	5.52	$11.03 per share	1.70
NVAX Novavax	$682.16M	1.77	N/A	N/A	($3.89) per share	-1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Crescent Biopharma	-$37.88M	-$46.00	N/A	N/A	N/A	N/A	-293.92%	-206.20%	N/A
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
INVA Innoviva	$23.39M	-$1.01	N/A	12.08	N/A	-16.15%	15.77%	8.41%	7/30/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.82	93.38	0.09	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)

Latest CBIO, INVA, NVAX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	N/A	N/A	N/A	$1.13 million	N/A
8/14/2025	Q2 2025	NVAX Novavax	-$0.12	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	INVA Innoviva	$0.43	N/A	N/A	N/A	$87.10 million	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Crescent Biopharma	N/A	2.29	2.29
CLDX Celldex Therapeutics	N/A	21.67	21.67
INVA Innoviva	0.40	2.48	2.30
NVAX Novavax	N/A	2.06	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Crescent Biopharma	75.19%
CLDX Celldex Therapeutics	N/A
INVA Innoviva	99.12%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
CBIO Crescent Biopharma	4.00%
CLDX Celldex Therapeutics	4.40%
INVA Innoviva	2.25%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable

CBIO, INVA, NVAX, and CLDX Headlines

Recent News About These Companies

Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

3 hours ago | finanznachrichten.de

Novavax stock rises after promising H5N1 vaccine preclinical results

July 25 at 9:58 AM | investing.com

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

July 24 at 6:46 PM | zacks.com

Novavax Sees Unusually Large Options Volume (NASDAQ:NVAX)

July 24 at 11:39 AM | marketbeat.com

Novavax's H5N1 vaccine shows promise with single-dose option

July 24 at 11:11 AM | investing.com

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

July 24 at 11:02 AM | benzinga.com

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

July 24 at 8:00 AM | prnewswire.com

Bank of America Lowers Novavax (NASDAQ:NVAX) Price Target to $9.00

July 22 at 1:47 PM | marketbeat.com

Novavax (NVAX) Price Target Lowered by B of A Securities | NVAX Stock News

July 22 at 1:46 PM | gurufocus.com

Hussman Strategic Advisors Inc. Grows Stock Position in Novavax, Inc. (NASDAQ:NVAX)

July 19, 2025 | marketbeat.com

Novavax Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 17, 2025 | marketwatch.com

Novavax (NVAX) Rises Higher Than Market: Key Facts

July 15, 2025 | msn.com

45,000 Shares in Novavax, Inc. (NASDAQ:NVAX) Purchased by DekaBank Deutsche Girozentrale

July 15, 2025 | marketbeat.com

Novavax (NVAX) Rises Higher Than Market: Key Facts

July 14, 2025 | zacks.com

BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT

July 13, 2025 | insidermonkey.com

13 Cheap Stocks with Huge Upside Potential

July 12, 2025 | insidermonkey.com

Novavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Hold" by Brokerages

July 12, 2025 | marketbeat.com

Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth

July 11, 2025 | seekingalpha.com

2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet

July 11, 2025 | fool.com

Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating

July 10, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO, INVA, NVAX, and CLDX Company Descriptions

Crescent Biopharma NASDAQ:CBIO

$13.29 +0.27 (+2.07%)

As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Celldex Therapeutics NASDAQ:CLDX

$23.35 +0.13 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$22.89 -0.46 (-1.97%)

As of 07:12 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Innoviva NASDAQ:INVA

$18.72 -0.20 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$18.72 0.00 (0.00%)

As of 04:11 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Novavax NASDAQ:NVAX

$7.47 -0.17 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$7.47 +0.00 (+0.01%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time